The individual was admitted with complaints of presence of intermittent confusion. Laboratory evaluations detected gene variant Tyr955Cys. Clinical monitoring is ongoing.
Upon examination, presence of chronic distal sensory impairment, clinical signs of chronic juvenile onset, clinical signs of sudden cholestasis, episodic motor axonal neuropathy observed were noted. Further imaging and laboratory tests identified gene variant A467T and W748S. The patient was started on a tailored therapeutic plan.
A medical history of moderate distal sensory impairment symptoms, persistent rigidity symptoms was documented. Genetic analysis confirmed gene variant A467T and W748S. Supportive care and follow-up were recommended.
Upon examination, persistent motor axonal neuropathy manifestation, history of chronic rigidity, history of mild juvenile onset, progressive cerebral visual impairment detected were noted. Further imaging and laboratory tests identified gene variant c.752C>T p.T251I and c.1760C>T p.P587L. The patient was started on a tailored therapeutic plan.
Upon examination, persistent prolonged partial thromboplastin time were noted. Further imaging and laboratory tests identified gene variant c.1399G>A p.Ala467Thr and c.3626_3629dupGATA. The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with intermittent cholestasis symptoms, presence of acute motor axonal neuropathy, mild cerebral visual impairment symptoms. Diagnostic workup revealed gene variant A467T and W748S. Treatment was initiated accordingly.
Upon examination, episodic rigidity, diagnosed with severe cerebral visual impairment, episodic depression condition were noted. Further imaging and laboratory tests identified gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 − 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of history of progressive confusion, presence of acute depression, prolonged partial thromboplastin time, episodic cerebral visual impairment. Laboratory evaluations detected gene variant c3239G>C p.Ser1080Thr. Clinical monitoring is ongoing.
Initial symptoms included intermittent motor axonal neuropathy detected, presence of intermittent cholestasis. Subsequent investigations showed gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). Management involved both pharmacological and rehabilitative approaches.
Upon examination, history of progressive cerebral visual impairment, mild rigidity were noted. Further imaging and laboratory tests identified gene variant c.2584G>A p.A862T and c.830A>T p.H277L. The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with history of chronic depression, clinical signs of chronic juvenile onset, progressive cerebral visual impairment condition, severe cholestasis. Diagnostic workup revealed gene variant p.A467T and c.2157+5_6GC>AG. Treatment was initiated accordingly.
A medical history of diagnosed with episodic confusion, history of episodic cerebral visual impairment, diagnosed with progressive cholestasis was documented. Genetic analysis confirmed gene variant c.1399G>A p.Ala467Thr and c.2542G>A p.Gly848Ser. Supportive care and follow-up were recommended.
The patient presented to the clinic with history of chronic cerebral visual impairment, history of moderate depression, history of severe motor axonal neuropathy. Diagnostic workup revealed gene variant T251I/P587L and R807C. Treatment was initiated accordingly.
Upon examination, severe eeg with occipital epileptiform discharges condition, moderate rigidity detected were noted. Further imaging and laboratory tests identified gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). The patient was started on a tailored therapeutic plan.
A medical history of persistent depression observed, history of severe prolonged partial thromboplastin time, presence of mild motor axonal neuropathy was documented. Genetic analysis confirmed gene variant c.679C>T p.R227W and c.2542G>A p.G848S. Supportive care and follow-up were recommended.
A medical history of progressive rigidity condition, progressive eeg with occipital epileptiform discharges symptoms, intermittent cerebral visual impairment manifestation was documented. Genetic analysis confirmed gene variant c.1399G>A p.Ala467Thr and c.2542G>A p.Gly848Ser. Supportive care and follow-up were recommended.
The patient presented to the clinic with progressive distal sensory impairment manifestation, confusion condition. Diagnostic workup revealed gene variant c.679C>T p.R227W and c.2542G>A p.G848S. Treatment was initiated accordingly.
The patient presented to the clinic with persistent cerebral visual impairment condition, clinical signs of sudden cholestasis. Diagnostic workup revealed gene variant 1399G >A A467T and 2243G >C W748S. Treatment was initiated accordingly.
Upon examination, mild cerebral visual impairment, clinical signs of persistent motor axonal neuropathy, chronic depression observed, intermittent eeg with occipital epileptiform discharges were noted. Further imaging and laboratory tests identified gene variant R853W and G737R. The patient was started on a tailored therapeutic plan.
Initial symptoms included history of intermittent distal sensory impairment, severe juvenile onset condition, presence of acute prolonged partial thromboplastin time, eeg with occipital epileptiform discharges symptoms. Subsequent investigations showed gene variant W748S. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of clinical signs of cerebral visual impairment, moderate rigidity observed, persistent confusion symptoms, moderate motor axonal neuropathy condition. Laboratory evaluations detected gene variant c.1288A>T p.M430L and c.2752T>C p.W918R. Clinical monitoring is ongoing.
The patient presented to the clinic with clinical signs of mild cholestasis, presence of acute depression, moderate rigidity symptoms. Diagnostic workup revealed gene variant A467T. Treatment was initiated accordingly.
A medical history of severe depression observed was documented. Genetic analysis confirmed gene variant c.1156C>T p.R386C and c.2794C>T p.H932Y. Supportive care and follow-up were recommended.
Initial symptoms included distal sensory impairment condition. Subsequent investigations showed gene variant 1399G→A (A467T). Management involved both pharmacological and rehabilitative approaches.
Upon examination, presence of chronic juvenile onset, presence of episodic prolonged partial thromboplastin time, diagnosed with severe depression were noted. Further imaging and laboratory tests identified . The patient was started on a tailored therapeutic plan.
Upon examination, presence of acute cholestasis were noted. Further imaging and laboratory tests identified gene variant p.Arg1096His (c.3287G>A) and p.Arg953Cys (c.2857C>T). The patient was started on a tailored therapeutic plan.
Initial symptoms included history of persistent eeg with occipital epileptiform discharges, presence of sudden juvenile onset, persistent motor axonal neuropathy. Subsequent investigations showed gene variant R853W and G737R. Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with presence of sudden eeg with occipital epileptiform discharges. Diagnostic workup revealed gene variant A467T and W748S. Treatment was initiated accordingly.
The individual was admitted with complaints of episodic cerebral visual impairment manifestation, sudden confusion detected, mild rigidity symptoms. Laboratory evaluations detected gene variant c. 2243G>C (p. W748S). Clinical monitoring is ongoing.
The individual was admitted with complaints of severe eeg with occipital epileptiform discharges manifestation, progressive depression. Laboratory evaluations detected gene variant c.752C>T (p.T251I) and c.3572A>G (p.K1191R). Clinical monitoring is ongoing.
The individual was admitted with complaints of episodic motor axonal neuropathy symptoms, mild distal sensory impairment condition, history of sudden eeg with occipital epileptiform discharges. Laboratory evaluations detected gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. Clinical monitoring is ongoing.
A medical history of moderate motor axonal neuropathy condition was documented. Genetic analysis confirmed gene variant c.752C>T (p.T251I) and c.3572A>G (p.K1191R). Supportive care and follow-up were recommended.
Upon examination, presence of severe rigidity, moderate distal sensory impairment condition, sudden prolonged partial thromboplastin time detected, presence of chronic confusion were noted. Further imaging and laboratory tests identified gene variant p.Arg1096His (c.3287G>A) and p.Arg953Cys (c.2857C>T). The patient was started on a tailored therapeutic plan.
Upon examination, progressive depression manifestation, diagnosed with severe rigidity were noted. Further imaging and laboratory tests identified gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). The patient was started on a tailored therapeutic plan.
Initial symptoms included presence of sudden rigidity, persistent confusion detected. Subsequent investigations showed gene variant 1399G→A (A467T). Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with intermittent rigidity condition, presence of mild motor axonal neuropathy. Diagnostic workup revealed gene variant p.A467T and c.2157+5_6GC>AG. Treatment was initiated accordingly.
Upon examination, acute motor axonal neuropathy were noted. Further imaging and laboratory tests identified gene variant p.A467T and c.2157+5_6GC>AG. The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with diagnosed with eeg with occipital epileptiform discharges, history of intermittent juvenile onset, history of moderate rigidity, presence of severe cholestasis. Diagnostic workup revealed gene variant c.752C>T (p.T251I) and c.2542G>A (p.G848S). Treatment was initiated accordingly.
Initial symptoms included presence of cerebral visual impairment. Subsequent investigations showed gene variant c.1156C>T p.R386C and c.2794C>T p.H932Y. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of diagnosed with progressive cholestasis, progressive prolonged partial thromboplastin time detected, moderate depression symptoms, clinical signs of moderate eeg with occipital epileptiform discharges. Laboratory evaluations detected gene variant c.2584G>A p.A862T and c.830A>T p.H277L. Clinical monitoring is ongoing.
A medical history of severe confusion symptoms was documented. Genetic analysis confirmed gene variant 1868T>G  L623W and 2263A>G K755E. Supportive care and follow-up were recommended.
The patient presented to the clinic with episodic prolonged partial thromboplastin time observed, moderate distal sensory impairment condition. Diagnostic workup revealed gene variant R853W and G737R. Treatment was initiated accordingly.
A medical history of presence of severe motor axonal neuropathy, prolonged partial thromboplastin time manifestation, diagnosed with chronic rigidity was documented. Genetic analysis confirmed gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 − 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. Supportive care and follow-up were recommended.
A medical history of intermittent distal sensory impairment condition was documented. Genetic analysis confirmed gene variant T251I/P587L and R807C. Supportive care and follow-up were recommended.
A medical history of clinical signs of progressive motor axonal neuropathy, sudden depression was documented. Genetic analysis confirmed gene variant c. 2243G>C (p. W748S). Supportive care and follow-up were recommended.
A medical history of diagnosed with severe rigidity, intermittent juvenile onset symptoms, chronic motor axonal neuropathy condition, intermittent eeg with occipital epileptiform discharges was documented. Genetic analysis confirmed gene variant c.3102delG (p.Lys1035Serfs*59) and c.3286C>T (p.Arg1096Cys). Supportive care and follow-up were recommended.
Initial symptoms included intermittent confusion manifestation, clinical signs of sudden motor axonal neuropathy, clinical signs of mild cholestasis, intermittent cerebral visual impairment condition. Subsequent investigations showed gene variant c.2243G>C. Management involved both pharmacological and rehabilitative approaches.
Upon examination, moderate cholestasis symptoms, history of intermittent motor axonal neuropathy, clinical signs of mild confusion were noted. Further imaging and laboratory tests identified gene variant c.3102delG (p.Lys1035Serfs*59) and c.3286C>T (p.Arg1096Cys). The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of diagnosed with moderate rigidity. Laboratory evaluations detected gene variant A467T. Clinical monitoring is ongoing.
A medical history of history of severe prolonged partial thromboplastin time, chronic distal sensory impairment was documented. Genetic analysis confirmed gene variant p.Arg953Cys. Supportive care and follow-up were recommended.
A medical history of presence of mild distal sensory impairment, persistent prolonged partial thromboplastin time condition, acute rigidity condition was documented. Genetic analysis confirmed gene variant P765T. Supportive care and follow-up were recommended.
The individual was admitted with complaints of diagnosed with persistent confusion, sudden cerebral visual impairment condition. Laboratory evaluations detected gene variant c.752C>T (p.T251I) and c.3572A>G (p.K1191R). Clinical monitoring is ongoing.
A medical history of diagnosed with moderate eeg with occipital epileptiform discharges was documented. Genetic analysis confirmed gene variant c.1156C>T p.R386C and c.2794C>T p.H932Y. Supportive care and follow-up were recommended.
A medical history of intermittent rigidity manifestation was documented. Genetic analysis confirmed gene variant c.3643+1G>A and c.2396C>A (p.S799Y). Supportive care and follow-up were recommended.
The patient presented to the clinic with chronic confusion detected. Diagnostic workup revealed gene variant c.3643+1G>A and c.2396C>A (p.S799Y). Treatment was initiated accordingly.
Upon examination, history of episodic cholestasis were noted. Further imaging and laboratory tests identified gene variant c911T > G (p. L304R) and 3240-3242 duplication (pR1081dup). The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with mild cholestasis manifestation, episodic distal sensory impairment, persistent motor axonal neuropathy detected, diagnosed with moderate prolonged partial thromboplastin time. Diagnostic workup revealed gene variant (c.2542G > A) p.G848S and (c.1399G > A) p.A467T. Treatment was initiated accordingly.
Initial symptoms included acute rigidity symptoms, clinical signs of sudden motor axonal neuropathy. Subsequent investigations showed gene variant c.3286C>T (p.Arg1096Cys). Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included moderate distal sensory impairment, severe eeg with occipital epileptiform discharges. Subsequent investigations showed gene variant P765T. Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with chronic cerebral visual impairment observed. Diagnostic workup revealed gene variant c.1156C>T p.R386C and c.2794C>T p.H932Y. Treatment was initiated accordingly.
Upon examination, chronic prolonged partial thromboplastin time detected, presence of intermittent depression, acute motor axonal neuropathy symptoms were noted. Further imaging and laboratory tests identified gene variant C752T (T251I) and C1760T (P587L). The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of presence of persistent rigidity, moderate cholestasis detected, presence of mild confusion. Laboratory evaluations detected gene variant c3239G>C p.Ser1080Thr. Clinical monitoring is ongoing.
A medical history of clinical signs of moderate cerebral visual impairment was documented. Genetic analysis confirmed gene variant c.752C>T p.T251I and c.1760C>T p.P587L. Supportive care and follow-up were recommended.
Initial symptoms included clinical signs of intermittent juvenile onset. Subsequent investigations showed gene variant c.1399G>A p.Ala467Thr and c.3626_3629dupGATA. Management involved both pharmacological and rehabilitative approaches.
Upon examination, presence of acute depression, progressive prolonged partial thromboplastin time condition, presence of chronic distal sensory impairment were noted. Further imaging and laboratory tests identified . The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with diagnosed with motor axonal neuropathy, presence of moderate depression. Diagnostic workup revealed gene variant T251I/P587L and R807C. Treatment was initiated accordingly.
Initial symptoms included progressive eeg with occipital epileptiform discharges detected, intermittent cerebral visual impairment condition, presence of intermittent juvenile onset, persistent prolonged partial thromboplastin time condition. Subsequent investigations showed gene variant c.1399G>A p.Ala467Thr and c.3626_3629dupGATA. Management involved both pharmacological and rehabilitative approaches.
A medical history of history of sudden rigidity, episodic motor axonal neuropathy symptoms, moderate prolonged partial thromboplastin time manifestation, history of moderate cerebral visual impairment was documented. Genetic analysis confirmed gene variant A467T. Supportive care and follow-up were recommended.
Upon examination, mild eeg with occipital epileptiform discharges symptoms, persistent confusion symptoms, diagnosed with severe depression, episodic distal sensory impairment symptoms were noted. Further imaging and laboratory tests identified gene variant C752T (T251I) and C1760T (P587L). The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with progressive confusion condition, diagnosed with intermittent juvenile onset. Diagnostic workup revealed gene variant W748S and c.3643+2T>C. Treatment was initiated accordingly.
The patient presented to the clinic with sudden cerebral visual impairment, clinical signs of intermittent distal sensory impairment, clinical signs of intermittent rigidity. Diagnostic workup revealed gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 − 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. Treatment was initiated accordingly.
Upon examination, history of acute rigidity were noted. Further imaging and laboratory tests identified gene variant c.3311C>G (p.S1104C) and c.2542G>A (p.G848S). The patient was started on a tailored therapeutic plan.
Initial symptoms included chronic distal sensory impairment observed, diagnosed with episodic rigidity, severe juvenile onset symptoms, motor axonal neuropathy. Subsequent investigations showed . Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of intermittent eeg with occipital epileptiform discharges detected. Laboratory evaluations detected gene variant 1399G>A A467T and 3573G>T K1191N. Clinical monitoring is ongoing.
A medical history of acute juvenile onset condition was documented. Genetic analysis confirmed . Supportive care and follow-up were recommended.
Initial symptoms included persistent confusion detected, history of sudden depression, chronic distal sensory impairment manifestation, persistent rigidity condition. Subsequent investigations showed gene variant c.1399G>A p.Ala467Thr and c.3626_3629dupGATA. Management involved both pharmacological and rehabilitative approaches.
A medical history of progressive distal sensory impairment detected was documented. Genetic analysis confirmed gene variant p.Arg953Cys. Supportive care and follow-up were recommended.
Initial symptoms included clinical signs of persistent depression, severe prolonged partial thromboplastin time, mild juvenile onset condition. Subsequent investigations showed gene variant 1399G>A A467T and 3573G>T K1191N. Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with episodic rigidity observed, moderate cholestasis observed, clinical signs of severe prolonged partial thromboplastin time, clinical signs of episodic depression. Diagnostic workup revealed gene variant 1399G>A A467T and 3573G>T K1191N. Treatment was initiated accordingly.
Initial symptoms included moderate motor axonal neuropathy detected. Subsequent investigations showed gene variant 1399G >A A467T and 2243G >C W748S. Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with history of severe motor axonal neuropathy, acute depression observed, clinical signs of severe cerebral visual impairment. Diagnostic workup revealed gene variant W748S. Treatment was initiated accordingly.
The individual was admitted with complaints of acute distal sensory impairment condition, mild prolonged partial thromboplastin time. Laboratory evaluations detected gene variant A467T and W748S. Clinical monitoring is ongoing.
The patient presented to the clinic with presence of persistent depression, severe cholestasis, clinical signs of episodic motor axonal neuropathy, progressive rigidity condition. Diagnostic workup revealed gene variant c.752C>T (p.T251I) and c.3572A>G (p.K1191R). Treatment was initiated accordingly.
Initial symptoms included moderate depression condition, intermittent rigidity symptoms, clinical signs of progressive cholestasis, progressive eeg with occipital epileptiform discharges observed. Subsequent investigations showed gene variant c.1535A>T p.K512M. Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included intermittent confusion symptoms, history of sudden eeg with occipital epileptiform discharges, episodic distal sensory impairment observed. Subsequent investigations showed gene variant c.3286C>T (p.Arg1096Cys). Management involved both pharmacological and rehabilitative approaches.
Upon examination, clinical signs of progressive cerebral visual impairment were noted. Further imaging and laboratory tests identified gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 − 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. The patient was started on a tailored therapeutic plan.
A medical history of presence of chronic eeg with occipital epileptiform discharges, juvenile onset condition was documented. Genetic analysis confirmed gene variant A467T. Supportive care and follow-up were recommended.
Upon examination, mild eeg with occipital epileptiform discharges detected, persistent rigidity symptoms, mild cerebral visual impairment symptoms, intermittent distal sensory impairment detected were noted. Further imaging and laboratory tests identified gene variant 1868T>G  L623W and 2263A>G K755E. The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with history of severe confusion, presence of sudden eeg with occipital epileptiform discharges. Diagnostic workup revealed gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. Treatment was initiated accordingly.
The individual was admitted with complaints of history of sudden eeg with occipital epileptiform discharges. Laboratory evaluations detected gene variant c.752C>T (p.T251I) and c.3572A>G (p.K1191R). Clinical monitoring is ongoing.
A medical history of mild depression condition, acute juvenile onset condition, presence of mild eeg with occipital epileptiform discharges, persistent distal sensory impairment condition was documented. Genetic analysis confirmed gene variant c.1288A>T p.M430L and c.2752T>C p.W918R. Supportive care and follow-up were recommended.
The individual was admitted with complaints of severe distal sensory impairment observed, diagnosed with chronic depression. Laboratory evaluations detected gene variant A467T and W748S. Clinical monitoring is ongoing.
A medical history of clinical signs of episodic depression, mild cerebral visual impairment was documented. Genetic analysis confirmed gene variant W748S and c.3643+2T>C. Supportive care and follow-up were recommended.
The patient presented to the clinic with clinical signs of episodic eeg with occipital epileptiform discharges, episodic prolonged partial thromboplastin time, sudden depression symptoms, presence of acute rigidity. Diagnostic workup revealed gene variant c.679C>T p.R227W and c.2542G>A p.G848S. Treatment was initiated accordingly.
A medical history of severe rigidity, distal sensory impairment, history of chronic cerebral visual impairment, moderate cholestasis manifestation was documented. Genetic analysis confirmed gene variant c.1156C>T p.R386C and c.2794C>T p.H932Y. Supportive care and follow-up were recommended.
A medical history of intermittent rigidity detected, moderate cholestasis condition was documented. Genetic analysis confirmed gene variant Tyr955Cys. Supportive care and follow-up were recommended.
Initial symptoms included diagnosed with severe rigidity, mild distal sensory impairment symptoms, sudden depression condition, severe cerebral visual impairment observed. Subsequent investigations showed gene variant c.3102delG (p.Lys1035Serfs*59) and c.3286C>T (p.Arg1096Cys). Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included episodic distal sensory impairment observed, presence of severe motor axonal neuropathy, prolonged partial thromboplastin time observed. Subsequent investigations showed gene variant C752T (T251I) and C1760T (P587L). Management involved both pharmacological and rehabilitative approaches.
A medical history of presence of chronic distal sensory impairment, history of sudden rigidity, severe eeg with occipital epileptiform discharges symptoms, history of severe depression was documented. Genetic analysis confirmed gene variant c.752C>T (p.T251I) and c.3572A>G (p.K1191R). Supportive care and follow-up were recommended.
The patient presented to the clinic with diagnosed with severe rigidity. Diagnostic workup revealed gene variant c. 2243G>C (p. W748S). Treatment was initiated accordingly.
A medical history of severe cholestasis manifestation, diagnosed with progressive depression, persistent confusion symptoms, episodic juvenile onset was documented. Genetic analysis confirmed gene variant c911T > G (p. L304R) and 3240-3242 duplication (pR1081dup). Supportive care and follow-up were recommended.
Upon examination, mild depression observed, clinical signs of mild cerebral visual impairment were noted. Further imaging and laboratory tests identified gene variant P765T. The patient was started on a tailored therapeutic plan.
Upon examination, clinical signs of mild juvenile onset were noted. Further imaging and laboratory tests identified gene variant c.3102delG (p.Lys1035Serfs*59) and c.3286C>T (p.Arg1096Cys). The patient was started on a tailored therapeutic plan.
A medical history of diagnosed with mild prolonged partial thromboplastin time, history of episodic confusion, juvenile onset condition, diagnosed with persistent cerebral visual impairment was documented. Genetic analysis confirmed . Supportive care and follow-up were recommended.
A medical history of mild prolonged partial thromboplastin time symptoms was documented. Genetic analysis confirmed gene variant (c.2542G > A) p.G848S and (c.1399G > A) p.A467T. Supportive care and follow-up were recommended.
The patient presented to the clinic with history of moderate juvenile onset, persistent eeg with occipital epileptiform discharges condition. Diagnostic workup revealed gene variant c. 2243G>C (p. W748S). Treatment was initiated accordingly.
Upon examination, acute rigidity detected were noted. Further imaging and laboratory tests identified gene variant P765T. The patient was started on a tailored therapeutic plan.
Upon examination, episodic distal sensory impairment symptoms, chronic confusion, intermittent eeg with occipital epileptiform discharges observed were noted. Further imaging and laboratory tests identified gene variant c.1535A>T p.K512M. The patient was started on a tailored therapeutic plan.
A medical history of presence of acute eeg with occipital epileptiform discharges, chronic distal sensory impairment manifestation was documented. Genetic analysis confirmed . Supportive care and follow-up were recommended.
The individual was admitted with complaints of distal sensory impairment symptoms, mild rigidity, progressive cholestasis detected, clinical signs of eeg with occipital epileptiform discharges. Laboratory evaluations detected gene variant P765T. Clinical monitoring is ongoing.
Initial symptoms included presence of mild juvenile onset, presence of persistent eeg with occipital epileptiform discharges, mild cerebral visual impairment symptoms. Subsequent investigations showed gene variant 1399G>A A467T and 3573G>T K1191N. Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with clinical signs of rigidity. Diagnostic workup revealed gene variant 1399G→A (A467T). Treatment was initiated accordingly.
The patient presented to the clinic with mild juvenile onset manifestation, chronic prolonged partial thromboplastin time symptoms. Diagnostic workup revealed . Treatment was initiated accordingly.
Upon examination, history of persistent prolonged partial thromboplastin time, moderate eeg with occipital epileptiform discharges observed, history of progressive cerebral visual impairment were noted. Further imaging and laboratory tests identified gene variant c.1156C>T p.R386C and c.2794C>T p.H932Y. The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of sudden cerebral visual impairment symptoms, severe eeg with occipital epileptiform discharges, history of progressive confusion. Laboratory evaluations detected gene variant c3239G>C p.Ser1080Thr. Clinical monitoring is ongoing.
The individual was admitted with complaints of chronic cholestasis. Laboratory evaluations detected gene variant Tyr955Cys. Clinical monitoring is ongoing.
Initial symptoms included mild distal sensory impairment condition, diagnosed with intermittent cholestasis. Subsequent investigations showed gene variant A467T and W748S. Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included progressive prolonged partial thromboplastin time detected. Subsequent investigations showed gene variant c.2993C>T p.998S>L and c.3550G>C p.1184D>H. Management involved both pharmacological and rehabilitative approaches.
Upon examination, progressive motor axonal neuropathy manifestation were noted. Further imaging and laboratory tests identified gene variant A467T. The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of history of severe cerebral visual impairment, persistent rigidity detected, presence of severe motor axonal neuropathy. Laboratory evaluations detected gene variant C752T (T251I) and C1760T (P587L). Clinical monitoring is ongoing.
Initial symptoms included clinical signs of moderate distal sensory impairment, sudden cholestasis detected, progressive prolonged partial thromboplastin time observed, presence of progressive juvenile onset. Subsequent investigations showed gene variant 1399G→A (A467T). Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included intermittent cholestasis condition, diagnosed with mild prolonged partial thromboplastin time. Subsequent investigations showed gene variant P765T. Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with progressive prolonged partial thromboplastin time detected, severe juvenile onset symptoms, progressive motor axonal neuropathy condition, presence of chronic depression. Diagnostic workup revealed gene variant C752T (T251I) and C1760T (P587L). Treatment was initiated accordingly.
Upon examination, history of chronic motor axonal neuropathy, distal sensory impairment manifestation, chronic cerebral visual impairment symptoms were noted. Further imaging and laboratory tests identified gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). The patient was started on a tailored therapeutic plan.
Upon examination, chronic prolonged partial thromboplastin time were noted. Further imaging and laboratory tests identified gene variant c.752C>T (p.T251I) and c.3572A>G (p.K1191R). The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with episodic rigidity detected, sudden eeg with occipital epileptiform discharges manifestation, moderate depression condition, clinical signs of intermittent motor axonal neuropathy. Diagnostic workup revealed gene variant 1399G >A A467T and 2243G >C W748S. Treatment was initiated accordingly.
Initial symptoms included prolonged partial thromboplastin time manifestation, clinical signs of episodic depression, history of sudden rigidity, intermittent juvenile onset observed. Subsequent investigations showed gene variant 1868T>G  L623W and 2263A>G K755E. Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included sudden prolonged partial thromboplastin time manifestation, mild rigidity observed, severe confusion symptoms, presence of episodic cholestasis. Subsequent investigations showed gene variant c.1288A>T p.M430L and c.2752T>C p.W918R. Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with persistent confusion symptoms, chronic motor axonal neuropathy condition, clinical signs of acute cerebral visual impairment, clinical signs of moderate eeg with occipital epileptiform discharges. Diagnostic workup revealed gene variant A467T. Treatment was initiated accordingly.
The individual was admitted with complaints of persistent cerebral visual impairment, distal sensory impairment manifestation, acute motor axonal neuropathy manifestation. Laboratory evaluations detected gene variant A467T. Clinical monitoring is ongoing.
A medical history of intermittent motor axonal neuropathy condition, diagnosed with severe juvenile onset, mild eeg with occipital epileptiform discharges manifestation, diagnosed with mild distal sensory impairment was documented. Genetic analysis confirmed gene variant T251I/P587L and R807C. Supportive care and follow-up were recommended.
Upon examination, diagnosed with sudden juvenile onset, persistent rigidity manifestation were noted. Further imaging and laboratory tests identified gene variant c. 2243G>C (p. W748S). The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with chronic distal sensory impairment observed, clinical signs of chronic prolonged partial thromboplastin time. Diagnostic workup revealed gene variant 1399G→A (A467T). Treatment was initiated accordingly.
The individual was admitted with complaints of depression condition, clinical signs of persistent cholestasis, diagnosed with sudden cerebral visual impairment, moderate eeg with occipital epileptiform discharges manifestation. Laboratory evaluations detected gene variant c.3643+1G>A and c.2396C>A (p.S799Y). Clinical monitoring is ongoing.
The individual was admitted with complaints of clinical signs of progressive eeg with occipital epileptiform discharges. Laboratory evaluations detected gene variant R853W and G737R. Clinical monitoring is ongoing.
Upon examination, sudden depression were noted. Further imaging and laboratory tests identified . The patient was started on a tailored therapeutic plan.
Upon examination, prolonged partial thromboplastin time observed, sudden motor axonal neuropathy detected, clinical signs of moderate distal sensory impairment were noted. Further imaging and laboratory tests identified gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). The patient was started on a tailored therapeutic plan.
A medical history of history of depression, diagnosed with episodic confusion, progressive eeg with occipital epileptiform discharges, moderate juvenile onset symptoms was documented. Genetic analysis confirmed . Supportive care and follow-up were recommended.
Initial symptoms included clinical signs of cholestasis, diagnosed with prolonged partial thromboplastin time, acute juvenile onset condition, diagnosed with persistent motor axonal neuropathy. Subsequent investigations showed gene variant 1399G >A A467T and 2243G >C W748S. Management involved both pharmacological and rehabilitative approaches.
Upon examination, moderate cerebral visual impairment symptoms, sudden prolonged partial thromboplastin time observed, persistent confusion manifestation, episodic rigidity observed were noted. Further imaging and laboratory tests identified gene variant R853W and G737R. The patient was started on a tailored therapeutic plan.
A medical history of presence of mild cerebral visual impairment, acute prolonged partial thromboplastin time detected was documented. Genetic analysis confirmed gene variant c.2993C>T p.998S>L and c.3550G>C p.1184D>H. Supportive care and follow-up were recommended.
A medical history of history of progressive juvenile onset, cerebral visual impairment manifestation, moderate motor axonal neuropathy manifestation, presence of sudden cholestasis was documented. Genetic analysis confirmed gene variant A467T. Supportive care and follow-up were recommended.
A medical history of episodic distal sensory impairment condition, history of acute rigidity, persistent depression detected, history of prolonged partial thromboplastin time was documented. Genetic analysis confirmed gene variant c.752C>T (p.T251I) and c.2542G>A (p.G848S). Supportive care and follow-up were recommended.
A medical history of mild cholestasis was documented. Genetic analysis confirmed gene variant C752T (T251I) and C1760T (P587L). Supportive care and follow-up were recommended.
The individual was admitted with complaints of diagnosed with sudden cerebral visual impairment, persistent prolonged partial thromboplastin time condition. Laboratory evaluations detected gene variant c.2864A>G (p.Tyr955Cys). Clinical monitoring is ongoing.
Initial symptoms included diagnosed with persistent motor axonal neuropathy, presence of chronic distal sensory impairment, episodic cholestasis observed, chronic cerebral visual impairment symptoms. Subsequent investigations showed gene variant c.2864A>G (p.Tyr955Cys). Management involved both pharmacological and rehabilitative approaches.
A medical history of acute depression detected, prolonged partial thromboplastin time condition, intermittent confusion condition was documented. Genetic analysis confirmed gene variant Tyr955Cys. Supportive care and follow-up were recommended.
The patient presented to the clinic with intermittent cholestasis symptoms, acute prolonged partial thromboplastin time detected, moderate motor axonal neuropathy observed, moderate rigidity manifestation. Diagnostic workup revealed gene variant A467T. Treatment was initiated accordingly.
Upon examination, mild cholestasis symptoms, presence of sudden rigidity, clinical signs of episodic motor axonal neuropathy were noted. Further imaging and laboratory tests identified gene variant c.3643+1G>A and c.2396C>A (p.S799Y). The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of clinical signs of moderate eeg with occipital epileptiform discharges, moderate rigidity symptoms. Laboratory evaluations detected gene variant A467T and W748S. Clinical monitoring is ongoing.
Initial symptoms included clinical signs of progressive cholestasis, history of severe rigidity. Subsequent investigations showed gene variant c.2864A>G (p.Tyr955Cys). Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with sudden confusion symptoms, sudden cerebral visual impairment, chronic distal sensory impairment manifestation. Diagnostic workup revealed gene variant c.1399G>A p.Ala467Thr and c.2542G>A p.Gly848Ser. Treatment was initiated accordingly.
The individual was admitted with complaints of persistent juvenile onset observed, presence of acute distal sensory impairment. Laboratory evaluations detected gene variant p.Arg953Cys. Clinical monitoring is ongoing.
A medical history of presence of mild confusion was documented. Genetic analysis confirmed gene variant T251I/P587L and R807C. Supportive care and follow-up were recommended.
The patient presented to the clinic with clinical signs of acute rigidity. Diagnostic workup revealed gene variant c.1399G>A p.Ala467Thr and c.2542G>A p.Gly848Ser. Treatment was initiated accordingly.
The patient presented to the clinic with persistent distal sensory impairment condition, presence of severe rigidity. Diagnostic workup revealed gene variant W748S. Treatment was initiated accordingly.
A medical history of sudden juvenile onset observed was documented. Genetic analysis confirmed gene variant R853W and G737R. Supportive care and follow-up were recommended.
The individual was admitted with complaints of clinical signs of moderate prolonged partial thromboplastin time, history of moderate confusion, chronic motor axonal neuropathy observed. Laboratory evaluations detected gene variant W748S and c.3643+2T>C. Clinical monitoring is ongoing.
A medical history of presence of episodic cerebral visual impairment was documented. Genetic analysis confirmed gene variant R853W and G737R. Supportive care and follow-up were recommended.
The individual was admitted with complaints of presence of chronic confusion. Laboratory evaluations detected gene variant c.752C>T (p.T251I) and c.2542G>A (p.G848S). Clinical monitoring is ongoing.
The individual was admitted with complaints of history of distal sensory impairment, acute prolonged partial thromboplastin time symptoms, intermittent rigidity detected, intermittent cerebral visual impairment. Laboratory evaluations detected gene variant 1399G >A A467T and 2243G >C W748S. Clinical monitoring is ongoing.
A medical history of diagnosed with rigidity, acute distal sensory impairment manifestation, progressive depression symptoms was documented. Genetic analysis confirmed gene variant A467T and W748S. Supportive care and follow-up were recommended.
Initial symptoms included history of sudden cholestasis, intermittent confusion manifestation, severe depression symptoms. Subsequent investigations showed gene variant c.1288A>T and c.2752T>C. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of clinical signs of severe depression, persistent motor axonal neuropathy, acute rigidity, presence of cholestasis. Laboratory evaluations detected gene variant c3239G>C p.Ser1080Thr. Clinical monitoring is ongoing.
The patient presented to the clinic with acute eeg with occipital epileptiform discharges condition, diagnosed with episodic rigidity, history of chronic depression. Diagnostic workup revealed gene variant c.2243G>C p.Trp748Ser. Treatment was initiated accordingly.
Initial symptoms included progressive depression condition, severe cholestasis condition. Subsequent investigations showed . Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included progressive cerebral visual impairment manifestation, moderate eeg with occipital epileptiform discharges manifestation, diagnosed with intermittent prolonged partial thromboplastin time. Subsequent investigations showed gene variant R853W and G737R. Management involved both pharmacological and rehabilitative approaches.
Upon examination, diagnosed with moderate cholestasis, persistent confusion symptoms, eeg with occipital epileptiform discharges condition were noted. Further imaging and laboratory tests identified gene variant p.Arg1096His (c.3287G>A) and p.Arg953Cys (c.2857C>T). The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of intermittent cerebral visual impairment detected, acute distal sensory impairment manifestation, clinical signs of persistent motor axonal neuropathy. Laboratory evaluations detected gene variant C752T (T251I) and C1760T (P587L). Clinical monitoring is ongoing.
The patient presented to the clinic with presence of severe confusion, persistent prolonged partial thromboplastin time condition, severe distal sensory impairment manifestation, sudden rigidity detected. Diagnostic workup revealed gene variant c.1399G>A (p.A467T) and c.3285C>G (p.S1095R). Treatment was initiated accordingly.
The patient presented to the clinic with episodic distal sensory impairment detected, juvenile onset symptoms. Diagnostic workup revealed gene variant c.2584G>A p.A862T and c.830A>T p.H277L. Treatment was initiated accordingly.
A medical history of progressive juvenile onset manifestation was documented. Genetic analysis confirmed gene variant c.2243G>C p.Trp748Ser. Supportive care and follow-up were recommended.
Upon examination, history of progressive depression, history of acute eeg with occipital epileptiform discharges, intermittent motor axonal neuropathy, severe juvenile onset condition were noted. Further imaging and laboratory tests identified gene variant A467T and W748S. The patient was started on a tailored therapeutic plan.
Upon examination, persistent juvenile onset observed, sudden prolonged partial thromboplastin time manifestation, presence of acute cholestasis were noted. Further imaging and laboratory tests identified gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 − 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. The patient was started on a tailored therapeutic plan.
Initial symptoms included mild prolonged partial thromboplastin time symptoms, persistent juvenile onset observed, history of depression. Subsequent investigations showed gene variant A467T and W748S. Management involved both pharmacological and rehabilitative approaches.
A medical history of presence of sudden cerebral visual impairment was documented. Genetic analysis confirmed gene variant A467T and W748S. Supportive care and follow-up were recommended.
The individual was admitted with complaints of chronic cholestasis observed, chronic eeg with occipital epileptiform discharges condition, presence of chronic distal sensory impairment. Laboratory evaluations detected gene variant Tyr955Cys. Clinical monitoring is ongoing.
The individual was admitted with complaints of diagnosed with mild eeg with occipital epileptiform discharges, clinical signs of persistent depression. Laboratory evaluations detected gene variant c.2243G>C. Clinical monitoring is ongoing.
Upon examination, history of chronic cholestasis, presence of moderate depression were noted. Further imaging and laboratory tests identified gene variant A467T and W748S. The patient was started on a tailored therapeutic plan.
Upon examination, presence of acute eeg with occipital epileptiform discharges were noted. Further imaging and laboratory tests identified gene variant c.3102delG (p.Lys1035Serfs*59) and c.3286C>T (p.Arg1096Cys). The patient was started on a tailored therapeutic plan.
Initial symptoms included clinical signs of moderate juvenile onset, diagnosed with moderate depression. Subsequent investigations showed gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of chronic motor axonal neuropathy condition. Laboratory evaluations detected gene variant c.1399G>A (p.A467T) and c.3285C>G (p.S1095R). Clinical monitoring is ongoing.
Initial symptoms included clinical signs of eeg with occipital epileptiform discharges, persistent prolonged partial thromboplastin time, intermittent motor axonal neuropathy observed. Subsequent investigations showed gene variant p.Arg953Cys. Management involved both pharmacological and rehabilitative approaches.
A medical history of episodic juvenile onset, clinical signs of persistent motor axonal neuropathy, diagnosed with mild distal sensory impairment, diagnosed with sudden cerebral visual impairment was documented. Genetic analysis confirmed gene variant p.Arg1096His (c.3287G>A) and p.Arg953Cys (c.2857C>T). Supportive care and follow-up were recommended.
The patient presented to the clinic with persistent cholestasis manifestation, episodic depression condition, intermittent eeg with occipital epileptiform discharges observed, progressive cerebral visual impairment symptoms. Diagnostic workup revealed gene variant R853W and G737R. Treatment was initiated accordingly.
Initial symptoms included mild distal sensory impairment condition. Subsequent investigations showed gene variant c.3286C>T (p.Arg1096Cys). Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with moderate cerebral visual impairment condition, history of moderate juvenile onset, moderate eeg with occipital epileptiform discharges observed. Diagnostic workup revealed . Treatment was initiated accordingly.
Upon examination, acute cerebral visual impairment detected were noted. Further imaging and laboratory tests identified gene variant p.Arg953Cys. The patient was started on a tailored therapeutic plan.
A medical history of episodic juvenile onset condition was documented. Genetic analysis confirmed gene variant W748S. Supportive care and follow-up were recommended.
A medical history of diagnosed with mild depression was documented. Genetic analysis confirmed gene variant c. 2243G>C (p. W748S). Supportive care and follow-up were recommended.
The individual was admitted with complaints of presence of persistent prolonged partial thromboplastin time, sudden confusion manifestation, chronic cholestasis manifestation. Laboratory evaluations detected gene variant W748S. Clinical monitoring is ongoing.
Upon examination, sudden cerebral visual impairment observed, progressive prolonged partial thromboplastin time observed, mild eeg with occipital epileptiform discharges were noted. Further imaging and laboratory tests identified gene variant 1399G >A A467T and 2243G >C W748S. The patient was started on a tailored therapeutic plan.
Initial symptoms included mild rigidity observed. Subsequent investigations showed gene variant c911T > G (p. L304R) and 3240-3242 duplication (pR1081dup). Management involved both pharmacological and rehabilitative approaches.
A medical history of persistent confusion detected, presence of progressive cholestasis, diagnosed with episodic cerebral visual impairment, clinical signs of severe rigidity was documented. Genetic analysis confirmed gene variant c.2243G>C p.Trp748Ser. Supportive care and follow-up were recommended.
Initial symptoms included presence of intermittent prolonged partial thromboplastin time, sudden confusion. Subsequent investigations showed gene variant 1868T>G  L623W and 2263A>G K755E. Management involved both pharmacological and rehabilitative approaches.
Upon examination, diagnosed with episodic confusion were noted. Further imaging and laboratory tests identified gene variant W748S. The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of progressive confusion observed, moderate juvenile onset symptoms, mild motor axonal neuropathy symptoms, presence of mild distal sensory impairment. Laboratory evaluations detected gene variant 1399G >A A467T and 2243G >C W748S. Clinical monitoring is ongoing.
A medical history of presence of persistent eeg with occipital epileptiform discharges, clinical signs of acute motor axonal neuropathy was documented. Genetic analysis confirmed gene variant c.2243G>C p.Trp748Ser. Supportive care and follow-up were recommended.
The individual was admitted with complaints of presence of persistent depression, history of acute juvenile onset, diagnosed with eeg with occipital epileptiform discharges, presence of chronic rigidity. Laboratory evaluations detected gene variant T251I/P587L and R807C. Clinical monitoring is ongoing.
The individual was admitted with complaints of presence of acute motor axonal neuropathy, history of rigidity. Laboratory evaluations detected gene variant C752T (T251I) and C1760T (P587L). Clinical monitoring is ongoing.
